Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData has released its new report, “Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global acute pain market. The report identifies the key trends shaping and driving the global acute pain market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global acute pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global acute pain therapeutics market was valued at $10.3 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.7% over the next seven years, to reach $14.2 billion by 2017. This slow growth is primarily attributed to a low treatment seeking behavior, disease awareness and usage of generic drugs. The current competitive landscape consists of branded, generic and off-label drugs.

Scope

The report provides information on the key drivers and challenges of the acute pain market. Its scope includes -

• Annualized global acute pain market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as NSAIDs, opioid receptors, AMPA and kainate sub-type receptors, kappa opioid receptors, conopeptide analogs, TRPV1 antagonists, Imidazoline I2 binding receptors, platelet glycoprotein IIb/IIIa receptors, Mu-opioid receptors, and ligand activated therapy.
• Analysis of the current and future competition in the global acute pain market. Key market players covered are AcelRX Pharmaceuticals, Inc., Acura Pharmaceuticals, Inc /King Pharmaceuticals, Cara Therapeutics, GlaxosmithKline, Grunenthal GMBH, QRX Pharma, Transdel Pharmaceuticals, Inc. and Xenome Ltd.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the acute pain therapeutics market.
• Analysis of key recent licensing and partnership agreements in acute pain therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global acute pain market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global acute pain market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global acute pain market landscape? – Identify, understand and capitalize.

Table of contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Acute Pain Therapeutics: Introduction 7
2.1 Disease Overview 7
2.2 Etiology and Pathophysiology 8
2.3 Signs and Symptoms 9
2.4 Diagnosis 10
2.4.1 Commonly Used Pain Scales 10
2.4.2 Commonly Used Diagnosis Tests 11
2.5 Treatment and Management Options 12
2.6 GlobalData Pipeline Report Guidance 13

3 Acute PainTherapeutics: Market Characterization 14
3.1 Acute Pain Therapeutics Market Size (2005-2010) – Global 14
3.2 Acute Pain Therapeutics Market Forecast (2010-2017) – Global 15
3.3 Acute Pain Therapeutics Market Size (2005-2010) – The US 16
3.4 Acute Pain Therapeutics Market Forecast (2010-2017) – The US 17
3.5 Acute Pain Therapeutics Market Size (2005-2010) – France 18
3.6 Acute Pain Therapeutics Market Forecast (2010-2017) – France 19
3.7 Acute Pain Therapeutics Market Size (2005-2010) – Germany 20
3.8 Acute Pain Therapeutics Market Forecast (2010-2017) – Germany 21
3.9 Acute Pain Therapeutics Market Size (2005-2010) – Italy 22
3.10 Acute Pain Therapeutics Market Forecast (2010-2017) – Italy 23
3.11 Acute Pain Therapeutics Market Size (2005-2010) – Spain 24
3.12 Acute Pain Therapeutics Market Forecast (2010-2017) – Spain 25
3.13 Acute Pain Therapeutics Market Size (2005-2010) – The UK 26
3.14 Acute Pain Therapeutics Market Forecast (2010-2017) – The UK 27
3.15 Acute Pain Therapeutics Market Size (2005-2010) – Japan 28
3.16 Acute Pain Therapeutics Market Forecast (2010-2017) – Japan 29
3.17 Drivers and Barriers for the Acute Pain Therapeutics Market 30
3.17.1 Drivers for the Acute Pain Therapeutics Market 30
3.17.2 Barriers for the Acute Pain Therapeutics Market 30
3.18 Opportunity and Unmet Need Analysis 31
3.19 Key Takeaway 32

4 Acute Pain Therapeutics: Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profiles for the Major Marketed Products in the Acute Pain Therapeutics Market 34
4.3.1 Celebrex (celecoxib) 34
4.3.2 Zipsor (diclofenac potassium) 34
4.3.3 Morphine 35
4.4 Key Takeaway 36

5 Acute Pain Therapeutics: Pipeline Assessment 37
5.1 Overview 37
5.2 Strategic Pipeline Assessment 37
5.3 Acute Pain Therapeutics Pipeline – Pipeline by Phases of Development 37
5.3.1 Acute Pain Therapeutics – Regulatory Filed Products 37
5.3.2 Acute Pain Therapeutics – Phase III Pipeline 38
5.3.3 Acute Pain Therapeutics – Phase II Pipeline 38
5.3.4 Acute Pain Therapeutics – Phase I Pipeline 38
5.3.5 Acute Pain Market – Discovery and Pre-Clinical Pipeline 39
5.3.6 Technology Trends Analytic Framework 39
5.4 Acute Pain Therapeutics Market – Pipeline by Mechanism of Action 41
5.5 Acute Pain Therapeutics – Promising Drugs Under Clinical Development 42
5.6 Molecule Profile for Promising Drugs Under Clinical Development 42
5.6.1 SB-705498 42
5.6.2 Acurox (oxycodone HCl/niacin) 43
5.6.3 Xen2174 44
5.7 Key Takeaway 45

6 Acute Pain Therapeutics: Clinical Trials Mapping 46
6.1.1 Clinical Trials by Region/Country (US, EU5 and Japan) 46
6.1.2 Clinical Trials by Phase 47
6.1.3 Clinical Trials by Trial Status 48
6.1.4 Prominent Sponsors 49
6.1.5 Top Companies Participating in Acute Pain Therapeutics Clinical Trials 51

7 Strategic Assessment 52
7.1.1 Key Events Impacting the Future Market 52
7.1.2 Acute Pain Therapeutics: Implications for Future Market Competition 53

8 Acute Pain Therapeutics: Future Players 54
8.1 Introduction 54
8.2 Company Profiles 55
8.2.1 Acura Pharmaceuticals, Inc. 55
8.2.2 Grunenthal GmbH 57
8.2.3 QRX Pharma 59
8.2.4 Transdel Pharmaceuticals, Inc. 60
8.2.5 Other Companies in the Acute Pain Therapeutics Market 61

9 Acute Pain Therapeutics: Licensing and Partnership Deals 62

10 Acute Pain Therapeutics: Appendix 67
10.1 Market Definitions 67
10.2 Abbreviations 67
10.3 Methodology 68
10.3.1 Coverage 68
10.3.2 Secondary Research 68
10.3.3 Forecasting 68
10.3.4 Primary Research 71
10.3.5 Expert Panel Validation 71
10.4 Contact Us 71
10.5 Disclaimer 71
10.6 Bibliography 72

List of Tables

Table 1: Differentiation of Acute Pain from Chronic Pain 7
Table 2: Causes and Epidemiology of Acute Pain 7
Table 3: Acute Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 14
Table 4: Acute Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017 15
Table 5: Acute Pain Therapeutics Market, The US, Revenue ($m), 2005–2010 16
Table 6: Acute Pain Therapeutics Market, The US, Forecasts ($m), 2010–2017 17
Table 7: Acute Pain Therapeutics Market, France, Revenue ($m), 2005–2010 18
Table 8: Acute Pain Therapeutics Market, France, Forecasts ($m), 2010–2017 19
Table 9: Acute Pain Therapeutics Market, Germany, Revenue ($m), 2005–2010 20
Table 10: Acute Pain Therapeutics Market, Germany, Forecasts ($m), 2010–2017 21
Table 11: Acute Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 22
Table 12: Acute Pain Therapeutics Market, Italy, Forecasts ($m), 2010–2017 23
Table 13: Acute Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 24
Table 14: Acute Pain Therapeutics Market, Spain, Forecasts ($m), 2010–2017 25
Table 15: Acute Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 26
Table 16: Acute Pain Therapeutics Market, The UK, Forecasts ($m), 2010–2017 27
Table 17: Acute Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 28
Table 18: Acute Pain Therapeutics Market, Japan, Forecast ($m), 2010–2017 29
Table 19: Zipsor Safety Trial 35
Table 20: Acute Pain Therapeutics – Regulatory Filed Products, 2010 37
Table 21: Acute Pain Therapeutics – Phase III Pipeline, 2010 38
Table 22: Acute Pain Therapeutics – Phase II Pipeline, 2010 38
Table 23: Acute Pain Therapeutics – Phase I Pipeline, 2010 38
Table 24: Acute PainTherapeutics – Discovery and Pre-Clinical Pipeline, 2010 39
Table 25: Acute Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2010 42
Table 26: Acute Pain Therapeutics – Clinical Trials by Country, 2010 46
Table 27: Acute Pain Therapeutics - Clinical Trials by Phase, 2010 47
Table 28: Acute Pain Therapeutics - Clinical Trials by Status, 2010 48
Table 29: Acute Pain Therapeutics - Prominent Sponsors, 2010 50
Table 30: Acute Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2010 51
Table 31: Acura Pharmaceuticals – Pain Management, Pipeline, 2010 56
Table 32: Acura Pharmaceuticals, Inc – Deals 56
Table 33: Grunenthal GmbH – Pain Management, Pipeline, 2010 57
Table 34: Grunenthal GmbH – Deals 58
Table 35: QRX Pharma– Pain Management, Pipeline, 2010 59
Table 36: Transdel Pharmaceuticals – Pain Management, Pipeline, 2010 60
Table 37: Transdel Pharmaceuticals, Inc. – Deals 61
Table 38: Acute Pain Therapeutics Market – Future Players 61
Table 39: Acute Pain Therapeutics, Global, Deals 62

List of Figures

Figure 1: Pathophysiology of Acute Pain 8
Figure 2: Signs and Symptoms of Acute Pain 9
Figure 3: Pain Measurement Scale – Numeric Rating Scale 10
Figure 4: Pain Measurement Scale – Visual Analog Scale 10
Figure 5: Pain Measurement Scale – Faces Rating Scale 11
Figure 6: WHO 3–Step Ladder for Pain Management 12
Figure 7: Acute Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010 14
Figure 8: Acute Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017 15
Figure 9: Acute Pain Therapeutics Market, The US, Revenue ($m), 2005–2010 16
Figure 10: Acute Pain Therapeutics Market, The US, Forecast ($m), 2010–2017 17
Figure 11: Acute Pain Therapeutics Market, France, Revenue ($m), 2005–2010 18
Figure 12: Acute Pain Therapeutics Market, France, Forecast ($m), 2010–2017 19
Figure 13: Acute Pain Therapeutics Market, Germany , Revenue ($m), 2005–2010 20
Figure 14: Acute Pain Therapeutics Market, Germany , Forecast ($m), 2010–2017 21
Figure 15: Acute Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010 22
Figure 16: Acute Pain Therapeutics Market, Italy, Forecast ($m), 2010–2017 23
Figure 17: Acute Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010 24
Figure 18: Acute Pain Therapeutics Market, Spain, Forecast ($m), 2010–2017 25
Figure 19: Acute Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010 26
Figure 20: Acute Pain Therapeutics Market, The UK, Forecast ($m), 2010–2017 27
Figure 21: Acute Pain Therapeutics Market, Japan, Revenue ($m), 2005–2010 28
Figure 22: Acute Pain Therapeutics Market, Japan, Forecast ($m), 2010–2017 29
Figure 23: Opportunity and Unmet Need in the Acute Pain Therapeutics Market, 2010 31
Figure 24: Acute Pain Therapeutics – Strategic Competitor Assessment, 2010 33
Figure 25: Acute Pain Therapeutics – Pipeline by Phase of Development, 2010 37
Figure 26: Acute Pain Therapeutics – Technology Trends Analytics Framework, 2010 39
Figure 27:Acute Pain Therapeutics – Technology Trends Analytics Framework – Description, 2010 40
Figure 28: Acute Pain Therapeutics – Pipeline by Mechanism of Action, 2010 41
Figure 29: Acute Pain Therapeutics – Clinical Trials by Country, 2010 46
Figure 30: Acute Pain Therapeutics - Clinical Trials by Phase, 2010 47
Figure 31: Acute Pain Therapeutics - Clinical Trials by Status, 2010 48
Figure 32: Acute Pain Therapeutics - Overall Sponsors, 2010 49
Figure 33: Acute Pain Therapeutics - Prominent Sponsors, 2010 49
Figure 34: Acute Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2010 51
Figure 35: Acute Pain Therapeutics Market, Drivers and Restraints 2010 52
Figure 36: Implications for Future Market Competition in the Acute Pain Market, 2010 53
Figure 37: Acute PainTherapeutics Market – Pipeline by Company, 2010 54
Figure 38: GlobalData Market Forecasting Model 70